News View all news
FDA approves first-of-its kind targeted RNA-based therapy to treat a rare disease
FDA has approved patisiran (Onpattro—Alnylam Pharmaceuticals) infusion for the treatment of peripheral nerve disease caused by hereditary transthyretin-mediated amyloidosis (hATTR) in adults. This is the first FDA-approved treatment for individuals with polyneuropathy caused by hATTR.
July 31, 2018
Retiring pharmacy giant gets a shout-out from Capitol Hill
Last week, Rep. Paul A. Gosar (R-AZ) stood on the floor of the U.S. House of Representatives to recognize the distinguished career of his constituent, RADM Pamela Schweitzer, PharmD, BCACP, as she…1 comment
APhA is the leading advocate for the pharmacy profession and a driving force in creating opportunities for pharmacists to play a key role in integrated patient care, and ensuring the profession is recognized as essential in optimal medication use. We strive to make your job as a pharmacist easier, by providing the latest industry news, continuing education and professional development opportunities, practice tools, and more, so that you can focus on caring for your patients.